Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Other Non-Current Assets (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Other Non-Current Assets data on record, last reported at $2.6 million in Q3 2025.

  • For Q3 2025, Other Non-Current Assets changed 0.0% year-over-year to $2.6 million; the TTM value through Sep 2025 reached $2.6 million, changed 0.0%, while the annual FY2024 figure was $4.4 million, 35.22% down from the prior year.
  • Other Non-Current Assets reached $2.6 million in Q3 2025 per ZNTL's latest filing, roughly flat from $2.6 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $10.2 million in Q1 2022 and bottomed at $2.6 million in Q2 2022.
  • Average Other Non-Current Assets over 4 years is $3.5 million, with a median of $2.6 million recorded in 2022.
  • The widest YoY moves for Other Non-Current Assets: up 159.54% in 2023, down 74.15% in 2023.
  • A 4-year view of Other Non-Current Assets shows it stood at $2.6 million in 2022, then surged by 159.54% to $6.8 million in 2023, then crashed by 35.22% to $4.4 million in 2024, then crashed by 40.53% to $2.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $2.6 million in Q3 2025, $2.6 million in Q2 2025, and $2.6 million in Q1 2025.